Elio Gregory Pizzutilo
@eliogregMD, Medical Oncologist @ospNiguarda #LCSM #ThoracicOncology Always find a way to have fun!
Similar User
@M_Tagliamento
@giusvisc
@margheambro1
@Al3ssandroRusso
@PrelajArsela
@AngeloDipa_
@ACortelliniMD
@fedenichetti
@RobertoFerrara_
@BlondeauxEva
@fedgiugliano
@Poggio_Fra
@MOcchipintiMD
@VGristina
@boutrosand
#ARTICUNO study finally published! @ESMO_Open 📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib 🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms 🔎 #E709 mut->lack of benefit
#lcsm: while small numbers from this phase 2 @JTOonline study, 5-year OS data seems to support 1L lorlatinib (76%!) With this & updated CROWN data, is it time to universally prescribe 1L lorlatinib for all?
Final survival results from phase II study of lorlatinib in #ALK NSCLC @JTOonline In treatment naive (n=30), 5y OS 76%. Post 2nd gen ALK TKI ± chemo (n=28), 5y OS 45%, median OS 37.4m. Post ≥2 ALK TKIs ± chemo (n=111), 5y OS 23%, median OS 19.2m. jto.org/article/S1556-…
Triple targeted therapy is effective for pts with EGFR-mutant NSCLC with acquired BRAF alterations, mainly among pts with BRAF class I mutations @ESMO_Open @myESMO #BRAF #NSCLC
🔥Press Release: Ph III IMforte trial shows PFS+OS benefit for maintenance lurbinectadin + atezo post chemo-immunotherapy for ES SCLC ADRIATIC, DELPHI, IMForte…finally, the SCLC landscape is changing @OncoAlert #LCSM investor.jazzpharma.com/news-releases/…
Excited to share our new study @Nature Very grateful for the support of our collaborators, pharma and biotech partners and members of the Skoulidis and Heymach labs. Special thanks to star fellow @_hanielaraujo and @minhtruongdo Thankful to our patients. @MDAndersonNews
Biggest medical discoveries of the week (🧵) 1/10 A complete map of the fruit fly brain - the biggest and most detailed to date 140,000 neurons, which connect through 55 million synapses to permit vision, movement, and memory formation (nature.com/articles/s4158…)
Germline EGFR T790M occurs more often in Whites, with a distinct radiological pattern and family history of lung cancer without smoking history. @KelseyPanMD @MDAndersonNews @lungoncdoc Journal of Thoracic Oncology jto.org/article/S1556-…
Very 'out of box' overview of ICI treatment duration in NSCLC from @g_mountzios at @LungSummit 2 years versus 5 years ICI : 186.000.000 euros spared: the cost to build a cancer hospital
New #OpenAccess perspective in @NatureRevCancer Defining precancer: a grand challenge for the cancer community nature.com/articles/s4156… A white paper resulting from @NCIprevention Precancer Think Tank. @sadhu1012 @IrenemGhobrial @TimRebbeck @AndyChanMD
Presented at #ESMO24: The monoclonal antibody ponsegromab increased weight, improved appetite, and allowed an increase in physical activity in patients with cancer who had lost more than 5% of body weight in the past 6 months. Full trial results: nej.md/3XE645a
Never seen such a wide difference in results administering the same drugs in the same population #ENCO-BRAF trial: PFS 10.9 mo (by investigators) #PHAROS trial: PFS 30.2 (by IRR) #ESMO2024 #lcsm #nsclc #braf
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in mBRAF Cancers Using Pharmacokinetics-Informed Dose Escalation @CD_AACR doi.org/10.1158/2159-8… 👏efficient dose escalation concept 👉compelling activity in resistent pts 🤩great to see the new generation…
⚖️Direct comparison: KEYNOTE-189 vs CheckMate 9LA 🔥NIPPON (JCOG2007): Chemo (C) + pembro vs C + nivo–ipi for 1st line NSCLC 🎙️Dr. Yoshimasa Shiraishi @LancetRespirMed 🎯Terminated early due to safety issues in nivo-ipi arm #LCSM @OncoAlert @JCOG_official thelancet.com/journals/lanre…
Important study ➡️one-third of patients with stage IIIN2 single station based CT, PETCT and EBUS staging actually have multistation N2 ➡️🤔definition of resectability should not be based on single vs multiple station @MatthewEvison1 @IASLC @EORTC
A new study from the UK demonstrates that single-station N2 NSCLC staged by PET/CT and EBUS lymph node sampling is actually multi-station N2 disease in 32-34% of cases. 🇬🇧 @_ShankarSiva @BTOGORG jtocrr.org/article/S2666-…
Ph II INSIGHT2 trial: Tepotinib+Osimertinib in MET amp+ EGFR+ NSCLC after 1L osimertinib: - 98pts MET amp+ - ORR 50% - TRAEs periph oedema 5%, ⬇️appetite 4%, ⬆️QT 4%, pneumonitis 3% - TR deaths 3% (pneu, ⬇️plat, resp failure) @TheLancet @OncoAlert #LCSM thelancet.com/journals/lanon…
More insights into the biology of METex14: Integrated genomic and transcriptomic profiling identifies four distinct molecular subtypes (MET, FGFR, immune, and bypass-driven) each with its own biology and distinct MET-TKI vulnerability @Nature_NPJ nature.com/articles/s4169…
Pete Souza was the Official Chief White House Photographer for the entire Presidency of Barack Obama. He took over 2 MILLION photos of Obama, as well as photos of Reagan & Bush. Today Musk suspended his account for posting this AP photo. Free speech my ass. #FreePeteSouza
Impact of #ALK fusion variants @JTOonline The specific fusion breakpoint has a profound impact. Variant 1 accounts for 50%, with TTD 20.3m whereas variant 3 accounts for 36% and TTD only 11.5m. Variant 3 plus TP53 co-mutation had TTD of only 7.4m. jto.org/article/S1556-…
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC with biomarkers of high-risk disease: a secondary analysis from MARIPOSA 💥In the presence of poor risk factors, amivantamab plus lazertinib has a longer PFS @OncoAlert annalsofoncology.org/article/S0923-…
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO) sciencedirect.com/science/articl…
United States Trends
- 1. Georgia 174 B posts
- 2. Haynes King 3.513 posts
- 3. Haynes King 3.513 posts
- 4. #SmackDown 49 B posts
- 5. Kirby 19,4 B posts
- 6. Iowa 17,7 B posts
- 7. Pritchard 3.436 posts
- 8. Raiders 78,7 B posts
- 9. Carson Beck 1.766 posts
- 10. #OPLive 2.566 posts
- 11. Nebraska 9.407 posts
- 12. Bobo 39,7 B posts
- 13. Ga Tech 1.563 posts
- 14. Athens 5.411 posts
- 15. Kaleb Johnson 1.105 posts
- 16. Arian Smith N/A
- 17. Shinsuke 3.599 posts
- 18. Trudeau 138 B posts
- 19. Dawgs 6.810 posts
- 20. Jeanty 26,7 B posts
Who to follow
-
Marco Tagliamento
@M_Tagliamento -
giuseppe viscardi
@giusvisc -
Margherita Ambrosini
@margheambro1 -
Alessandro Russo
@Al3ssandroRusso -
arsela prelaj
@PrelajArsela -
Angelo Dipasquale
@AngeloDipa_ -
Alessio Cortellini
@ACortelliniMD -
Federico Nichetti
@fedenichetti -
Roberto Ferrara
@RobertoFerrara_ -
Eva Blondeaux
@BlondeauxEva -
Federica Giugliano, MD
@fedgiugliano -
Francesca Poggio
@Poggio_Fra -
Mario Occhipinti
@MOcchipintiMD -
Valerio Gristina
@VGristina -
Andrea Boutros
@boutrosand
Something went wrong.
Something went wrong.